세계의 줄기세포 치료 시장 예측(-2027년) : 종류별(동종, 자가), 세포원별(지방조직 유래 MSC, 골수, 태반/제대), 치료 용도별(근골격, 창상, 수술, 심혈관, 신경)

The global stem cell therapy market is projected to reach USD 558 million by 2027 from USD 257 million in 2022, at a CAGR of 16.8% during the forecast period. Several companies are focusing on developing regenerative medicine due to the rising number of clinical trials conducted on stem cell therapies. The increasing number of clinical trials has largely taken place owing to the rising government and public & private investments for R&D in cell-based therapies, supportive regulatory framework, and accelerated approval provisions by the FDA in regenerative medicine R&D.

"The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, by type, during the forecast period"

The stem cell therapy market is segmented into allogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. Stem cells used for allogeneic stem cell therapy are obtained from sources other than the target patient, which is usually from a donor. In allogeneic stem cell therapy, one cell source can produce many doses, thus making allogeneic therapy economically viable and less time-consuming. Moreover, it is easier to scale up production processes for allogeneic therapy than for autologous therapy. Currently, more than ten approved commercialized allogeneic stem cell therapies are available globally.

"Bone Marrow-derived MSCs segment accounted for the highest CAGR"

Based on the cell source the global stem cell therapy market is segmented into adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources. Bone marrow-derived mesenchymal stem cells are the most preferred type for stem cell therapies. Bone marrow MSCs are readily available, require less in vitro processing, and can be used for autologous and allogeneic stem cell therapy. Over the last decade, the stem cell therapy market has witnessed high demand for several bone marrow-derived stem cell-based products for various therapeutic applications, including immune-deficiency syndromes, hemoglobinopathies, and metabolic disorders. This has collectively contributed the segment's growth.

"Asia Pacific: The fastest-growing country in the stem cell therapy market"

The stem cell therapy market is segmented into North America, Europe, Asia Pacific, RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. Rising cases of neurodegenerative disorders drive market growth for stem cell therapy products in India along with favorable government support for stem cell therapy products in South Korea have propelled the growth of Asia Pacific stem cell therapy market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: C-level - 25%, D-level - 20%, and Others - 55%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:

• Smith+Nephew (UK)
• MEDIPOST Co. Ltd. (South Korea)
• Anterogen Co. Ltd. (South Korea)
• CORESTEM (South Korea)
• Pharmicell Co. Ltd. (South Korea)
• NuVasive Inc. (US)
• RTI Surgical (US)
• AlloSource (US)
• JCR Pharmaceuticals Co. Ltd. (Japan)
• Takeda Pharmaceutical Company Limited (Japan)
• Holostem Terapie Avanzate Srl (Italy)
• Orthofix (US)
• Regrow Biosciences Pvt Ltd. (India)
• STEMPEUTICS RESEARCH PVT LTD. (India)
• Athersys (US)
• Mesoblast Ltd (Australia)
• Biorestorative Therapies Inc. (US)
• Pluristem Inc. (Israel)
• Brainstorm Cell Limited. (US)
• ViaCyte Inc. (US)
• Gamida Cell (US)
• Kangstem Biotech (South Korea)
• Hope Biosciences (US)
• Cellular Biomedicine Group (US)
• Personalized Stem Cells (US)

Research Coverage:

This report provides a detailed picture of the stem cell therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, therapeutic applications, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • FIGURE 1 STEM CELL THERAPY MARKET
  • 1.3.1 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • FIGURE 2 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: STEM CELL THERAPY MARKET
• 2.2 MARKET SIZE ESTIMATION
  • FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF STEM CELL THERAPY MARKET PLAYERS
  • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
  • FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021
• 2.3 GROWTH FORECAST
  • FIGURE 7 STEM CELL THERAPY MARKET: CAGR PROJECTIONS (2022-2027)
  • FIGURE 8 STEM CELL THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• 2.4 DATA TRIANGULATION
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
• 2.5 PRIMARY INSIGHTS
  • FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

• FIGURE 12 STEM CELL THERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
• FIGURE 13 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2022 VS. 2027 (USD MILLION)
• FIGURE 14 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2022 VS. 2026 (USD MILLION)
• FIGURE 15 GEOGRAPHICAL SNAPSHOT OF STEM CELL THERAPY MARKET

4 PREMIUM INSIGHTS

• 4.1 STEM CELL THERAPY MARKET OVERVIEW
  • FIGURE 16 INCREASING INVESTMENTS & FUNDING INITIATIVES FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH
• 4.2 NORTH AMERICA: STEM CELL THERAPY MARKET
  • FIGURE 17 ALLOGENEIC STEM CELL THERAPY TO COMMAND LARGEST SHARE IN 2021
• 4.3 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2022 VS. 2027 (USD MILLION)
  • FIGURE 18 BONE MARROW-DERIVED MSCS TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
  • FIGURE 19 MARKET DYNAMICS: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Availability of funding for stem cell research
  • TABLE 1 ICMR FUNDING FOR STEM CELL RESEARCH, 2019-2021 (USD)
  • FIGURE 20 STEM CELL RESEARCH FUNDING IN LAST 10 YEARS
  • TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016-2021 (USD MILLION)
    • 5.2.1.2 Increasing GMP certification approvals for cell therapy production facilities
  • TABLE 3 NEW GMP FACILITIES, 2017-2020
    • 5.2.1.3 Increasing clinical trials for stem cell-based therapies
  • FIGURE 21 NUMBER OF CLINICAL TRIALS (2015-2020)
  • FIGURE 22 CLINICAL TRIALS, BY PHASE
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Ethical concerns related to embryonic stem cells
    • 5.2.2.2 High cost of cell-based research
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emergence of iPSCs as an alternative to ESCs
    • 5.2.3.2 Growing demand for cell & gene therapies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Technical limitations associated with manufacturing processes
• 5.3 TECHNOLOGY ANALYSIS
  • TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES
• 5.4 VALUE CHAIN ANALYSIS
  • FIGURE 23 VALUE CHAIN ANALYSIS OF STEM CELL THERAPY MARKET
• 5.5 ROLE IN ECOSYSTEM
  • FIGURE 24 ECOSYSTEM MARKET MAP
• 5.6 SUPPLY CHAIN ANALYSIS
  • FIGURE 25 SUPPLY CHAIN ANALYSIS OF STEM CELL THERAPY MARKET
  • TABLE 5 SUPPLY CHAIN ANALYSIS: COMMERCIAL SCALE/KEY MANUFACTURERS
  • TABLE 6 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF SUPPLIERS
  • 5.7.4 BARGAINING POWER OF BUYERS
  • 5.7.5 INTENSITY OF COMPETITION RIVALRY
• 5.8 REGULATORY LANDSCAPE
  • 5.8.1 NORTH AMERICA
  • TABLE 7 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
  • 5.8.2 EUROPE
  • TABLE 8 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
  • 5.8.3 ASIA PACIFIC
  • TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
  • 5.8.4 REST OF THE WORLD
  • TABLE 10 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
• 5.9 PRICING ANALYSIS
  • 5.9.1 PRICING ANALYSIS
  • TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS
  • 5.9.2 AVERAGE SELLING PRICE TREND - STEM CELL THERAPY TREATMENT
• 5.10 PATENT ANALYSIS
  • FIGURE 26 PATENT ANALYSIS OF STEM CELL THERAPIES IN LAST 10 YEARS (2011-2020)
• 5.11 KEY CONFERENCES & EVENTS IN 2022-2023
  • 5.11.1 STEM CELL THERAPY CONFERENCES (2022-2023)
  • TABLE 12 STEM CELL THERAPY CONFERENCES (2022-2023)
• 5.12 DISRUPTIONS & TRENDS IMPACTING CUSTOMERS' BUSINESSES
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • FIGURE 27 KEY STAKEHOLDERS IN STEM CELL THERAPY MARKET
  • FIGURE 28 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 29 REVENUE SHIFT & NEW POCKET FOR STEM CELL THERAPY COMPANIES

6 STEM CELL THERAPY MARKET, BY TYPE

• 6.1 INTRODUCTION
  • TABLE 13 STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
• 6.2 ALLOGENEIC STEM CELL THERAPY
  • 6.2.1 FAVORABLE SCALING UP OF PRODUCTION PROCESSES TO DRIVE SEGMENT
  • TABLE 14 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 15 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 16 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 17 ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
• 6.3 AUTOLOGOUS STEM CELL THERAPY
  • 6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE SEGMENT
  • TABLE 18 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 19 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 20 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 21 ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

7 STEM CELL THERAPY MARKET, BY CELL SOURCE

• 7.1 INTRODUCTION
  • TABLE 22 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
• 7.2 ADIPOSE TISSUE-DERIVED MSCS
  • 7.2.1 PROPERTIES SUCH AS SIMPLIFIED HARVESTING & EASE OF ISOLATION TO DRIVE MARKET
  • TABLE 23 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 24 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 25 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 26 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020-2027 (USD MILLION)
• 7.3 BONE MARROW-DERIVED MSCS
  • 7.3.1 HIGH PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET
  • TABLE 27 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 28 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 29 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020-2027 (USD MILLION)
• 7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS
  • 7.4.1 LOWER CHANCES OF IMMUNE REJECTION TO SUPPORT MARKET
  • TABLE 31 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 32 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 33 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 34 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020-2027 (USD MILLION)
• 7.5 OTHER CELL SOURCES
  • TABLE 35 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 36 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 37 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020-2027 (USD MILLION)

8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION

• 8.1 INTRODUCTION
  • TABLE 39 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
• 8.2 MUSCULOSKELETAL DISORDERS
  • 8.2.1 RISING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET
  • TABLE 40 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 41 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 42 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
• 8.3 WOUNDS & INJURIES
  • 8.3.1 GROWING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH
  • TABLE 44 STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 45 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 46 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020-2027 (USD MILLION)
• 8.4 INFLAMMATORY & AUTOIMMUNE DISEASES
  • 8.4.1 INCREASING CLINICAL TRIALS FOR BONE MARROW-DERIVED MSCS TO SUPPORT MARKET GROWTH
  • TABLE 48 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 49 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 50 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & INFLAMMATORY DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
• 8.5 SURGERIES
  • 8.5.1 GROWING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH
  • TABLE 52 STEM CELL THERAPY MARKET FOR SURGERIES, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 53 NORTH AMERICA: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 54 EUROPE: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020-2027 (USD MILLION)
• 8.6 CARDIOVASCULAR DISEASES
  • 8.6.1 RISING DEMAND FOR CVD TREATMENTS TO SUPPORT MARKET GROWTH
  • TABLE 56 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 57 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 58 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
• 8.7 NEUROLOGICAL DISORDERS
  • 8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS TO SUPPORT MARKET GROWTH
  • TABLE 60 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 61 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 62 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
• 8.8 OTHER THERAPEUTIC APPLICATIONS
  • TABLE 64 STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 66 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

9 STEM CELL THERAPY MARKET, BY REGION

• 9.1 INTRODUCTION
  • TABLE 68 STEM CELL THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION)
• 9.2 NORTH AMERICA
  • FIGURE 30 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT
  • TABLE 69 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 70 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 71 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 72 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
  • 9.2.1 US
    • 9.2.1.1 Rising approvals for stem cell therapy products to drive market
  • FIGURE 31 NIH FUNDING IN LAST 10 YEARS (2011-2021)
  • TABLE 73 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 74 US: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 75 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
  • 9.2.2 CANADA
    • 9.2.2.1 Increasing government focus on targeted stem cell therapy treatment to drive market
  • TABLE 76 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 77 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 78 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
• 9.3 EUROPE
  • TABLE 79 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 80 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 81 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 82 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
  • 9.3.1 GERMANY
    • 9.3.1.1 Strong R&D base and growing focus on minimally invasive treatments to drive market
  • TABLE 83 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 84 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 85 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
  • 9.3.2 UK
    • 9.3.2.1 Rising adoption of cell-based therapies to drive market
  • TABLE 86 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 87 UK: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 88 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
  • 9.3.3 FRANCE
    • 9.3.3.1 Rising healthcare expenditure to support uptake of stem cell therapy products
  • TABLE 89 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 90 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 91 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
  • 9.3.4 REST OF EUROPE
  • TABLE 92 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 93 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 94 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
• 9.4 ASIA PACIFIC
  • FIGURE 32 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT
  • TABLE 95 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
  • 9.4.1 JAPAN
    • 9.4.1.1 Growing geriatric population and rapid regulatory processes to drive market
  • TABLE 98 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 99 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 100 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
  • 9.4.2 SOUTH KOREA
    • 9.4.2.1 Favorable government support for stem cell therapy products to support market growth
  • TABLE 101 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 102 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 103 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
  • 9.4.3 INDIA
    • 9.4.3.1 Rising cases of neurodegenerative disorders drive market
  • TABLE 104 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 105 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 106 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
  • 9.4.4 REST OF ASIA PACIFIC
  • TABLE 107 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 108 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 109 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)
• 9.5 REST OF THE WORLD
  • TABLE 110 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020-2027 (USD MILLION)
  • TABLE 111 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 112 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
  • FIGURE 33 STEM CELL THERAPY MARKET: STRATEGIES ADOPTED
• 10.3 REVENUE SHARE ANALYSIS
• 10.4 MARKET SHARE ANALYSIS (2021)
• 10.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS)
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • FIGURE 36 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR APPROVED PRODUCTS (2021)
• 10.6 COMPETITIVE BENCHMARKING
  • 10.6.1 STEM CELL THERAPY MARKET: A DETAILED LIST OF STARTUPS/SMES
  • TABLE 113 STEM CELL THERAPY MARKET: DETAILED LIST OF STARTUPS/SMES
  • 10.6.2 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES)
  • TABLE 114 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES]
• 10.7 COMPANY EVALUATION QUADRANT (SMES/START-UPS)
  • 10.7.1 PROGRESSIVE COMPANIES
  • 10.7.2 STARTING BLOCKS
  • 10.7.3 RESPONSIVE COMPANIES
  • 10.7.4 DYNAMIC COMPANIES
  • FIGURE 37 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR PRODUCTS UNDER PIPELINE (2021)
• 10.8 COMPANY PRODUCT FOOTPRINT ANALYSIS
  • TABLE 115 COMPANY PRODUCT FOOTPRINT
• 10.9 COMPANY FOOTPRINT OF MAJOR PLAYERS
  • TABLE 116 COMPANY REGIONAL FOOTPRINT
• 10.10 COMPETITIVE SCENARIO
  • TABLE 117 STEM CELL THERAPY MARKET: REGULATORY APPROVALS
  • TABLE 118 STEM CELL THERAPY MARKET: DEALS

11 COMPANY PROFILES

• 11.1 MAJOR PLAYERS
• (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
• 11.1.1 SMITH+NEPHEW
• TABLE 119 SMITH+NEPHEW: BUSINESS OVERVIEW
• FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2021)
• TABLE 120 SMITH+NEPHEW: PRODUCT OFFERINGS
• TABLE 121 SMITH+NEPHEW: DEALS
• 11.1.2 MEDIPOST CO., LTD.
• TABLE 122 MEDIPOST CO., LTD: BUSINESS OVERVIEW
• FIGURE 39 MEDIPOST CO., LTD: COMPANY SNAPSHOT (2019)
• TABLE 123 MEDIPOST CO., LTD: PRODUCT OFFERINGS
• TABLE 124 MEDIPOST CO., LTD: PRODUCT APPROVALS
• TABLE 125 MEDIPOST CO., LTD: DEALS
• TABLE 126 MEDIPOST CO., LTD: OTHERS
• TABLE 127 MEDIPOST CO., LTD: REGULATORY APPROVALS AND PATENTS
• 11.1.3 JCR PHARMACEUTICALS CO., LTD.
• TABLE 128 JCR PHARMACEUTICALS CO., LTD: BUSINESS OVERVIEW
• FIGURE 40 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2021)
• TABLE 129 JCR PHARMACEUTICALS CO., LTD: PRODUCT OFFERINGS
• 11.1.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED
• TABLE 130 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW
• FIGURE 41 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021)
• TABLE 131 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT OFFERINGS
• TABLE 132 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS
• TABLE 133 TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGULATORY APPROVALS
• 11.1.5 ANTEROGEN. CO., LTD.
• TABLE 134 ANTEROGEN CO., LTD: BUSINESS OVERVIEW
• TABLE 135 ANTEROGEN CO., LTD: PRODUCT OFFERINGS
• 11.1.6 CORESTEM
• TABLE 136 CORESTEM: BUSINESS OVERVIEW
• TABLE 137 CORESTEM: PRODUCT OFFERINGS
• TABLE 138 CORESTEM: REGULATORY APPROVALS
• 11.1.7 PHARMICELL CO., LTD.
• TABLE 139 PHARMICELL CO., LTD.: BUSINESS OVERVIEW
• TABLE 140 PHARMICELL CO., LTD.: PRODUCT OFFERINGS
• TABLE 141 PHARMICELL CO., LTD.: DEALS
• 11.1.8 NUVASIVE, INC.
• TABLE 142 NUVASIVE, INC: BUSINESS OVERVIEW
• FIGURE 42 NUVASIVE, INC: COMPANY SNAPSHOT (2021)
• TABLE 143 NUVASIVE, INC.: PRODUCT OFFERINGS
• 11.1.9 RTI SURGICAL
• TABLE 144 RTI SURGICAL: BUSINESS OVERVIEW
• TABLE 145 RTI SURGICAL: PRODUCT OFFERINGS
• 11.1.10 ALLOSOURCE
• TABLE 146 ALLOSOURCE: BUSINESS OVERVIEW
• TABLE 147 ALLOSOURCE: PRODUCT OFFERINGS
• 11.1.11 HOLOSTEM TERAPIE AVANZATE SRL
• TABLE 148 HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW
• TABLE 149 HOLOSTEM TERAPIE AVANZATE SRL: PRODUCT OFFERINGS
• 11.1.12 ORTHOFIX
• TABLE 150 ORTHOFIX: BUSINESS OVERVIEW
• FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2021)
• TABLE 151 ORTHOFIX: PRODUCT OFFERINGS
• 11.1.13 STEMPEUTICS RESEARCH
• TABLE 152 STEMPEUTICS RESEARCH: BUSINESS OVERVIEW
• TABLE 153 STEMPEUTICS RESEARCH: PRODUCT OFFERINGS
• 11.1.14 REGROW BIOSCIENCES PVT LTD.
• TABLE 154 REGROW BIOSCIENCES PVT LTD: BUSINESS OVERVIEW
• TABLE 155 REGROW BIOSCIENCES PVT LTD: PRODUCT OFFERINGS
• 11.2 OTHER PLAYERS (PRODUCTS IN PIPELINE)
  • 11.2.1 ATHERSYS, INC.
  • 11.2.2 MESOBLAST LTD
  • 11.2.3 BIORESTORATIVE THERAPIES, INC.
  • 11.2.4 PLURISTEM INC.
  • 11.2.5 BRAINSTORM CELL LIMITED.
  • 11.2.6 GAMIDA CELL
  • 11.2.7 VIACYTE, INC.
  • 11.2.8 KANGSTEM BIOTECH
  • 11.2.9 HOPE BIOSCIENCES
  • 11.2.10 CELLULAR BIOMEDICINE GROUP (CBMG)
  • 11.2.11 PERSONALIZED STEM CELLS
• *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS